BioCentury
ARTICLE | Clinical News

Jounce reports detailed data backing tumor-agnostic approach

April 4, 2019 11:56 PM UTC

Jounce reported detailed PFS and OS data at AACR for vopratelimab (JTX-2011) that support a tumor-agnostic approach for the ICOS agonist to select patient populations more likely to respond to the therapy.

At the American Association for Cancer Research meeting in Atlanta, Jounce Therapeutics Inc. (NASDAQ:JNCE) reported detailed data from the adaptive Phase I/II ICONIC trial to treat advanced solid tumors showing that vopratelimab led to median progression-free survival (PFS) of 6.2 months among 18 patients with the ICOS hi CD4 T cells biomarker vs. 2 months for the 32 patients with ICOS lo CD4 T cells. Median overall survival (OS) has not yet been reached in the ICOS hi CD4 T cell population vs. 9 months for the ICOS lo CD4 T cell population...